COVID-19 Research Paper Volume 12, Issue 22 pp 22413—22424

Estimating the release of inflammatory factors and use of glucocorticoid therapy for COVID-19 patients with comorbidities

Figure 2. Differences in inflammatory cytokines between severe COVID-19 patients with and without comorbidities. (A, B) There was no obvious difference in IL-2R and IL-4 level between the comorbidities and non-comorbidities groups. (C) IL-6 levels were significantly increased in the comorbidities group. (D, E) There was no obvious difference in IL-10 and TNF-α levels between the comorbidities and non-comorbidities groups. (F) The comorbidities group had significantly increased IFN-γ levels.